PURPOSE: Ivermectin is an antiparasitic drug that exhibits antitumor effects in preclinical studies, and as such is currently being repositioned for cancer treatment. However, divergences exist regarding its employed doses in preclinical works. Therefore, the aim of this study was to determine whether the antitumor effects of ivermectin are observable at clinically feasible drug concentrations. METHODS: Twenty-eight malignant cell lines were treated with 5 μM ivermectin. Cell viability, clonogenicity, cell cycle, cell death and pharmacological interaction with common cytotoxic drugs were assessed, as well as the consequences of its use on stem cell-enriched populations. The antitumor in vivo effects of ivermectin were also evaluated. RESULTS: The breast MDA-MB-231, MDA-MB-468, and MCF-7, and the ovarian SKOV-3, were the most sensitive cancer cell lines to ivermectin. Conversely, the prostate cancer cell line DU145 was the most resistant to its use. In the most sensitive cells, ivermectin induced cell cycle arrest at G0-G1 phase, with modulation of proteins associated with cell cycle control. Furthermore, ivermectin was synergistic with docetaxel, cyclophosphamide and tamoxifen. Ivermectin reduced both cell viability and colony formation capacity in the stem cell-enriched population as compared with the parental one. Finally, in tumor-bearing mice ivermectin successfully reduced both tumor size and weight. CONCLUSION: Our results on the antitumor effects of ivermectin support its clinical testing.
PURPOSE:Ivermectin is an antiparasitic drug that exhibits antitumor effects in preclinical studies, and as such is currently being repositioned for cancer treatment. However, divergences exist regarding its employed doses in preclinical works. Therefore, the aim of this study was to determine whether the antitumor effects of ivermectin are observable at clinically feasible drug concentrations. METHODS: Twenty-eight malignant cell lines were treated with 5 μM ivermectin. Cell viability, clonogenicity, cell cycle, cell death and pharmacological interaction with common cytotoxic drugs were assessed, as well as the consequences of its use on stem cell-enriched populations. The antitumor in vivo effects of ivermectin were also evaluated. RESULTS: The breast MDA-MB-231, MDA-MB-468, and MCF-7, and the ovarian SKOV-3, were the most sensitive cancer cell lines to ivermectin. Conversely, the prostate cancer cell line DU145 was the most resistant to its use. In the most sensitive cells, ivermectin induced cell cycle arrest at G0-G1 phase, with modulation of proteins associated with cell cycle control. Furthermore, ivermectin was synergistic with docetaxel, cyclophosphamide and tamoxifen. Ivermectin reduced both cell viability and colony formation capacity in the stem cell-enriched population as compared with the parental one. Finally, in tumor-bearing miceivermectin successfully reduced both tumor size and weight. CONCLUSION: Our results on the antitumor effects of ivermectin support its clinical testing.
Entities:
Keywords:
Cancer; Cancer stem cells; Drug repurposing; Ivermectin
Authors: J C Chabala; H Mrozik; R L Tolman; P Eskola; A Lusi; L H Peterson; M F Woods; M H Fisher; W C Campbell; J R Egerton; D A Ostlind Journal: J Med Chem Date: 1980-10 Impact factor: 7.446
Authors: Guadalupe Dominguez-Gomez; Alma Chavez-Blanco; Jose Luis Medina-Franco; Fernanda Saldivar-Gonzalez; Ytzel Flores-Torrontegui; Mandy Juarez; José Díaz-Chávez; Aurora Gonzalez-Fierro; Alfonso Dueñas-González Journal: Mol Med Rep Date: 2017-12-08 Impact factor: 2.952
Authors: Da Eun Lee; Hyeon Woong Kang; So Yi Kim; Myeong Jin Kim; Jae Woong Jeong; Woosol Chris Hong; Sungsoon Fang; Hyung Sun Kim; Yun Sun Lee; Hyo Jung Kim; Joon Seong Park Journal: Front Pharmacol Date: 2022-08-26 Impact factor: 5.988